TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
HAE

Haemonetics Corporation

Healthcare · Medical Devices

107.60$ +1.3% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Haemonetics Corporation (HAE)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 98.7% of the shares are freely tradable; institutional investors hold 108.4%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 108.4%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 1.2%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 98.7%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 7.4%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 46Mio.

Largest Shareholders

Institutions

Institutions HAE
Name Stake (%) Shares Change (%) Date
BlackRock Inc 12.35 5,619,979 -3.5 03/31/2026
Neuberger Berman Group LLC 7.83 3,560,918 -7.9 03/31/2026
AQR Capital Management LLC 7.38 3,356,543 +6.1 03/31/2026
Vanguard Portfolio Management, LLC 5.63 2,559,316 +0.0 03/31/2026
Vanguard Capital Management, LLC 4.59 2,090,389 +0.0 03/31/2026
Ariel Investments, LLC 4.53 2,060,966 +0.0 06/30/2026
State Street Corp 3.90 1,772,898 +2.5 03/31/2026
Dimensional Fund Advisors, Inc. 3.48 1,585,222 +19.5 06/30/2026
Citadel Advisors Llc 3.32 1,510,120 +485.0 06/30/2026

Funds

Funds HAE
Name Stake (%) Shares Change (%) Date
iShares Core S&P Mid-Cap ETF 3.58 1,627,459 +0.0 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider holdings

Insider holdings HAE
Person Role Shares Value As of Type
Abernathy Robert E Director 27,519 2,961,044 $ Jul 24, 2026 direct
Kroll Mark W Director 27,295 2,936,942 $ Jul 24, 2026 direct
Zane Ellen M Director 21,911 2,357,624 $ Jul 24, 2026 direct
Pomeroy Claire Director 19,410 2,088,516 $ Jul 24, 2026 direct
Coyle Michael J Director 17,932 1,929,483 $ Jul 24, 2026 direct
Johnson Lloyd Emerson Director 15,471 1,664,680 $ Jul 24, 2026 direct
Bryant Diane M Director 9,664 1,039,846 $ Jul 24, 2026 direct
Madaus Martin D Director 2,538 273,089 $ Jul 24, 2026 direct

Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.

Insiders

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
Jul 24, 2026 Madaus Martin D Director Other 2,538
Jul 24, 2026 Zane Ellen M Director Other 2,538
Jul 24, 2026 Pomeroy Claire Director Other 2,538
Jul 24, 2026 Kroll Mark W Director Other 2,538
Jul 24, 2026 Johnson Lloyd Emerson Director Other 2,538
Jul 24, 2026 Coyle Michael J Director Other 2,538
Jul 24, 2026 Bryant Diane M Director Other 2,538
Jul 24, 2026 Abernathy Robert E Director Other 2,538

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?